{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T15:28:52Z","timestamp":1762270132443},"reference-count":0,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"name":"Secretariat d\u2019Etat \u00e0 la Recherche Scientifique et Technique, Tunisia"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Mediators of Inflammation"],"published-print":{"date-parts":[[1998,1]]},"abstract":"<jats:p>The aim of this study was to quantify soluble Fas\/APO1 (sFas\/APO\u20101) protein in the serum of patients with Behcet\u2032s disease (BD) in active and inactive stages, compared with patients with systemic lupus erythematosus (SLE) and patients with rheumatoid arthritis (RA). Soluble Fas\/APO\u20101 was quantified using a sandwich enzyme\u2010linked immunosorbent assay. Increased serum sFas\/APO\u20101 levels were observed in active BD, compared with inactive BD, RA patients and SLE patients. Increased serum sFas\/APO\u20101 levels were correlated with the presence of neurologic manifestations or pulmonary involvement in active BD. In conclusion, increased levels of sFas\/APO\u20101 occurred frequently and exclusively in active BD patients. Preliminary evidence suggested that elevated levels of sFas\/APO\u20101 are associated with the clinical stage and clinical manifestations in BD.<\/jats:p>","DOI":"10.1080\/09629359891261","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T15:36:35Z","timestamp":1027697795000},"page":"111-114","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Levels of soluble Fas\/APO\u20101 in patients with Beh\u00e7et\u2032s disease"],"prefix":"10.1155","volume":"7","author":[{"given":"K.","family":"Hamzaoui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hamzaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Zakraoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Chabbou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[1998,1]]},"container-title":["Mediators of Inflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/mi\/1998\/279863.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1080\/09629359891261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T12:24:51Z","timestamp":1723119891000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1080\/09629359891261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,1]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1998,1]]}},"alternative-id":["10.1080\/09629359891261"],"URL":"https:\/\/doi.org\/10.1080\/09629359891261","archive":["Portico"],"relation":{},"ISSN":["0962-9351","1466-1861"],"issn-type":[{"type":"print","value":"0962-9351"},{"type":"electronic","value":"1466-1861"}],"subject":[],"published":{"date-parts":[[1998,1]]},"assertion":[{"value":"1998-01-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}